Published in
Elsevier, Lung Cancer, 2(84), p. 161-167, 2014
DOI: 10.1016/j.lungcan.2014.02.011
Links
Tools
Phase I/II trial of vorinostat (SAHA) and erlotinib for non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations after erlotinib progression
Journal article published in 2014 by
Noemi Reguart 
,
Rafael Rosell,
Felipe Cardenal,
Andres F. Cardona,
Dolores Isla ,
Ramon Palmero,
Teresa Moran,
Christian Rolfo ,
M. Cinta Pallarès,
Amelia Insa ,
Enric Carcereny,
Margarita Majem,
Javier De Castro ,
Cristina Queralt,
Miguel A. Molina
and other authors.
,
Rafael Rosell,
Felipe Cardenal,
Andres F. Cardona,
Dolores Isla ,
Ramon Palmero,
Teresa Moran,
Christian Rolfo ,
M. Cinta Pallarès,
Amelia Insa ,
Enric Carcereny,
Margarita Majem,
Javier De Castro ,
Cristina Queralt,
Miguel A. Molina
and other authors.
This paper was not found in any repository, but could be made available legally by the author.
Full text: Unavailable
Published version:
archiving forbidden
Data provided by 